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To determine the predictive value of a raised androgen level with an elevated anti-Müllerian hormone 
(AMH) for the diagnosis or exclusion of polycystic ovary syndrome (PCOS), a prospective cross-sectional 
study of 170 women (105 with PCOS type A and 65 normal) was undertaken. AMH was combined with 
one of, total serum testosterone (T); calculated free androgen index; salivary testosterone (salT); serum 
androstenedione (A); salivary androstenedione (salA). The diagnostic sensitivity and specificity of AMH 
(>35 pmol/l) alone for PCOS were 55% and 79% respectively. The diagnostic sensitivity and specificity 
of AMH (>35 pmol/l) with either an elevated T or raised FAI level for PCOS showed 100% specificity 
and a 100% positive predictive value. Conversely, diagnostic exclusion of PCOS was shown by an AMH 
<35 pmol/l with a normal T or FAI salivary testosterone giving 100% specificity and 100% positive 
predictive value. AMH with an elevated A or elevated salA level gave specificities of 87% and 94%, and 
positive predictive values 80% and 94%, respectively. Therefore, the combination of an AMH with a cut 
off of 35 pmol/l combined with a raised T and/or a FAI will confirm PCOS whilst a normal AMH with a 
normal T and/or FAI will exclude PCOS, thus addressing diagnostic uncertainty.
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting women of reproductive age 
and its prevalence varies according to the criteria used between 6% (NIH criteria) and 10% (Androgen Excess 
Society or Rotterdam society guidelines)1; however, it still remains a diagnosis only after the exclusion of other 
conditions2,3. Anti-Müllerian hormone (AMH) is produced in the granulosa cells by the pre-antral and small 
antral follicles and highly correlates to the antral follicle count. The antral follicle count is increased in PCOS 
and hence PCOS is associated with higher serum AMH values4; higher AMH levels are particularly associated 
with PCOS patients fulfilling all three diagnostic criteria5. It has been suggested that AMH may add value for the 
positive diagnosis of PCOS, with a meta-analysis suggesting a serum AMH cut-off level of 35 pmol/l that has a 
sensitivity of 79.4% and a specificity of 82.8%6. We have recently reported that the combination of a raised FAI 
with a raised salT identified 100% of PCOS patients in a biobank cohort, thought this was not found with serum 
A or salA7, though others have suggested that serum A reflects androgen excess in PCOS8 and has diagnostic 
value9. Therefore, the aim of this study was to look specifically if AMH would be complementary for the diagnosis 
of PCOS in combination with an elevated androgen levels (T or FAI or salT or A or salA) within this well-defined 
cohort of PCOS patients from the general population that fulfilled all 3 of the Rotterdam criteria.
Subjects and Methods
This was a cross sectional study involving 105 well characterised women with PCOS and 65 women without PCOS 
who presented sequentially and prospectively to the Department of Endocrinology and were recruited to the local 
PCOS biobank (ISRCTN70196169). All patients gave written informed consent. This study was approved by the 
Newcastle & North Tyneside Ethics committee. The diagnosis of PCOS was based on all three diagnostic criteria 
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of the Rotterdam consensus, namely clinical and biochemical evidence of hyperandrogenism (Ferriman-Gallwey 
score >8; free androgen index >4, total testosterone >1.5 nmol/l), oligomenorrhea or amenorrhea and polycystic 
ovaries on transvaginal ultrasound10, described as the type A phenotype in which AMH levels are reported to be 
highest5. Study participants had no concurrent illness, were not on any medication for the preceding 9 months 
and were not planning to conceive. Non-classical 21-hydroxylase deficiency, hyperprolactinemia, Cushing’s dis-
ease and androgen-secreting tumours were excluded by appropriate tests. All of the control women had regular 
periods, no clinical or biochemical hyperandrogenism, no polycystic ovaries on ultrasound, no significant back-
ground medical history and none of them were on any medications including oral contraceptive pills or over 
the counter medications. All women underwent a 75 g oral glucose tolerance test to exclude impaired glucose 
tolerance and type 2 diabetes. All women with PCOS and control women were Caucasian. Height, weight, waist 
circumference and body mass index (BMI) were performed according to WHO guidelines11.
Study measurements. Blood samples were centrifuged within 5 min of collection and were stored frozen 
at −80 °C pending analysis. All study measurements and analysis were performed in accordance with the relevant 
guidelines and regulations. Serum T and A were measured by LC/MS/MS on an Acquity UPLC system coupled 
to a Quattro Premier XE mass spectrometer (Waters, Manchester, UK). Sex hormone binding globulin (SHBG) 
was measured by an immunometric assay with fluorescence detection on the DPC Immulite 2000 analyzer using 
the manufacturer’s recommended protocol (upper limit of the reference range 2.0 nmol/l). The free androgen 
index (FAI) was calculated as the total testosterone × 100/SHBG. Serum insulin was assayed using a competitive 
chemiluminescent immunoassay performed on the manufacturer’s DPC Immulite 2000 analyzer (Euro/DPC, 
Llanberis, UK). The analytical sensitivity of the insulin assay was 2 μU/ml, the coefficient of variation was 6%, 
and there was no stated cross-reactivity with proinsulin. Plasma glucose was measured using a Synchron LX 
20 analyzer (Beckman-Coulter), using the manufacturer’s recommended protocol. The coefficient of variation 
for the assay was 1.2% at a mean glucose value of 5.3 mmol/liter. The insulin resistance was calculated using 
the HOMA method [HOMA-IR = (insulin × glucose)/22.5]. Anti-Müllerian hormone was measured using a 
Beckman Coulter Access automated immunoassay; between run precision was <3% across the range measured.
Collection and handling of saliva samples. This has been detailed previously for the saliva collection 
and for the salivary androgen measurement methodology7. In brief, participants were asked to spit or drool 
directly into a 4 mL sealable polystyrene tube and to provide at least 3 mL of saliva. Unstimulated saliva samples 
were used to avoid any assay interference. The “passive drool” technique was used for the collection of saliva 
rather than the ‘salivette’ method. Salivary testosterone and salivary androstendione were measured by LC-MS/
MS analysis performed using a Waters Acquity UPLC system coupled to a Waters Xevo TQS mass spectrometer, 
giving a lower limit of quantification of 5 pmol/L for salT and 6.25 pmol/l for salA with an inter and intra-assay 
precision coefficient of variation of <4% and <7.5%, respectively7.
Statistical analysis. Data trends were visually evaluated for AMH and for each androgen, and non-parametric 
tests were applied on data that violated the assumptions of normality when tested using Kolmogorov-Smirnov Test. 
Accordingly, comparative analysis evaluating androgen levels between PCOS cases and controls were performed 
using the non-parametric Mann-Whitney tests. Significance was defined at α = 0.05. All analyses were done using 
IBM-SPSS version 24.0. All values are given as (mean ± SD) unless specified. Sensitivity (true positive/(true posi-
tive + false negative)), specificity (true negative/true negative + false positive), positive predictive value (true pos-
itive/(true positive + false positive)) and negative predictive value (true negative/(true negative + false negative)) 
were calculated accordingly. It was suggested from a meta-analysis of the literature that an AMH greater than 
35 pmol/l was suggestive of a diagnosis of PCOS6 and therefore this value was used rather than the higher cut off of 
55 pmol/l recently suggested12. A biochemical diagnosis of PCOS was defined as requiring an AMH >35 pmol/l and 
a raised androgen (true positive), whilst the exclusion of PCOS was defined as an AMH <35 pmol/l and a normal 
androgen level in the control population (true negative). A false negative was defined as either having one of an 
AMH >35 pmol/l or an elevated androgen level in the PCOS population; a false positive was defined as an AMH 
>35 pmol/l and an elevated androgen in the control population.
Results
All PCOS women were categorized into a single phenotype according to the combination of the three Rotterdam’s 
Consensus Criteria. The baseline demographics of patients have been reported for this cohort7 (Table 1). As 
expected, patients with PCOS showed higher insulin levels, HOMA-IR, 2 hour glucose post oral glucose tolerance 
test (OGTT) values (p < 0.001) (Table 1). Serum T, FAI, A and salT were significantly elevated in PCOS compared 
to controls (p < 0.001). The sensitivity, specificity, positive and negative predictive values for AMH alone were 55%, 
78%, 80% and 52%. The sensitivity, specificity, positive and negative predictive values for AMH and T, FAI and 
salT are shown in Fig. 1. The combination of a raised AMH with either a raised serum T or raised FAI was 100% 
specific for a diagnosis of PCOS in this population with a positive predictive value of 100%; this was less robust for 
the salT with a specificity of 94% and a positive predictive value of 91%. Conversely, the combination of an AMH 
<35 pmol/l with either a normal T or FAI was 100% specific and with a 100% positive predictive value for the 
exclusion of a diagnosis of PCOS. The sensitivity, specificity, positive and negative predictive values for AMH and 
A and salT are shown in Fig. 1. The combination of a raised AMH with a raised serum A, or a raised AMH and a 
raised salA gave a specificity of 87% and 94%, respectively; a sensitivity of 43% and 23%, respectively, for a diagno-
sis of PCOS in this population, with positive and negative predictive values being correspondingly low.
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Discussion
This study shows an AMH above a conservative threshold of 35 pmol/l with either a raised T or a raised FAI 
identified 100% of PCOS women with type A phenotype with a 100% positive predictive value, though sensitivity 
was low. Conversely, but equally important, the combination of a an AMH less than 35 pmol/l with a normal T 
or normal salT excluded a diagnosis of PCOS with 100% specificity, but again the sensitivity was low. AMH with 
salT showed high specificity but the salT identified 3 control patients with an elevated level salT and AMH mak-
ing an apparent false positive, though this would have been addressed by a higher AMH cut off of 46 pmol/l (or 
higher)12. SalT correlates very closely with FAI and it would have been predicted that both would have had equal 
utility in combination with AMH7, though in this regard FAI would appear to be the better androgen to measure. 
This would appear to be the first time that a combination of 2 biochemical markers have shown 100% specificity 
for the diagnosis or the exclusion of PCOS, though this needs to be validated in a larger cohort and with the other 
phenotypes identified by the Rotterdam criteria, other than the single phenotype here.
The Rotterdam criteria are the most commonly used to make the diagnosis of PCOS but there is controversy 
in making a diagnosis of PCOS in adolescence and the perimenopause3, whilst the accuracy of androgen meas-
urements13 and the polycystic ovarian morphology14 may also contribute to diagnostic uncertainty for any given 
case. In addition, the diagnosis of PCOS can only be made once other causes have been excluded3; therefore, a 
biomarker or combination of biomarkers to allow a positive diagnosis of PCOS is of major interest to help make a 
positive diagnosis of PCOS and to reduce the uncertainty that may result for individual patients; AMH has been 
suggested to be such a biomarker6,12. AMH at a cut off of 55 pmol/l has been reported to have a high specificity 
and sensitivity and was robust for PCOS in older age groups12. A lower threshold of 35 pmol/l was reported to be 
of value in a meta-analysis; the specificity shown here was similar to the meta-analysis was similar (78% v 82%) 
though the sensitivity was less (55% v 79%), perhaps due to the different PCOS populations studied. These reports 
show the lack of standardisation and variability in the AMH assays that would result in differing cut off thresh-
olds1,15. This also highlights that there is not an AMH threshold cut off level that is diagnostic, in the absence of 
other factors, to positively make a 100% diagnosis of PCOS, nor to positively exclude the diagnosis. It is not clear 
how an AMH level should be incorporated into a PCOS diagnostic algorithm.
Positive aspects of this study included the significant number of subjects all with the type A phenotype for 
PCOS, fulfilling all 3 diagnostic criteria, and a homogeneous Caucasian population; AMH is noted to be the 
highest in this PCOS population5,16. The utility of this approach using only PCOS subjects with phenotype A 
was that if the AMH/androgen combination had not shown such specificity and positive predictive values then 
it would have certainly been less for the other PCOS phenotypes, and would therefore have no diagnostic dis-
criminatory value. All patients had polycystic ovaries on ultrasound and therefore it might have expected all of 
Parameters
Controls PCOS
p valueMedian IQR Median IQR
Age (years) 31.0 11.0 27.0 11.0 0.010*
BMI (kg/m2) 25.0 6.1 33.0 10.2 <0.001*
Waist Circumference (cm) 78.0 14.8 101.0 21.0 <0.001*
Hip Circumference (cm) 100.0 16.0 117.0 19.5 <0.001*
AMH (pmol/l) 18.1 24.8 40.0 42.7 <0.001*
Salivary testosterone (pmol/l) 13.1 10.0 18.5 15.0 <0.001*
Total Testosterone (nmol/L) 1.0 0.5 1.3 0.9 <0.001*
Salivary Androstenedione (pmol/l) 142.89 95.00 165.76 118.00 <0.001*
Androstenedione (nmol/L) 7.40 5.90 40.31 7.90 <0.001*
SHBG (nmol/L) 45.0 31.8 27.0 19.0 <0.001*
FAI (%) 2.2 1.9 4.5 5.3 <0.001*
FSH (IU/L) 5.6 3.6 4.9 2.8 0.099
LH (IU/L) 4.3 5.4 6.1 5.5 0.009*
Baseline Glucose (mmol/L) 4.5 0.6 4.7 0.5 0.001*
2 Hour Glucose (mmol/L) 4.9 1.3 5.6 1.8 <0.001*
Insulin (μIU/ml) 6.0 3.8 13.7 11.4 <0.001*
HOMA-IR 1.2 0.8 2.9 2.4 <0.001*
Table 1. Comparison of anthropometric and hormonal parameters of the 170 subjects involved in the 
study, 65 women without PCOS and 105 women with PCOS. The diagnosis of PCOS was based on all three 
diagnostic criteria of the Rotterdam consensus, namely clinical and biochemical evidence of hyperandrogenism 
(Ferriman-Gallwey score >8; free androgen index >4 respectively), oligomenorrhea or amenorrhea and 
polycystic ovaries on transvaginal ultrasound. These women therefore represented the phenotype with the 
greatest metabolic features. BMI – Body Mass Index; AMH- antiMullarian hormone; SHBG- sex hormone 
binding globulin; FAI–Free Androgen Index; FSH–Follicle Stimulating Hormone, LH–Leutenising hormone; 
HOMA-IR–Homeostasis model of assessment–insulin resistance To convert values for glucose to milligrams 
per deciliter, divide by 0.056. To convert values for insulin to picomoles per liter, multiply by 6. To convert 
values for testosterone to nanograms per deciliter, divide by 0.03467. To convert values for SHBG to micrograms 
per deciliter, divide by 34.7.
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the AMH values to be elevated. Why this was not the case is likely due to the observation that AMH values have 
been shown to be lower in anovulation and many of these patients may have been anovulatory, though this was 
not determined in this study, and AMH levels differ with age12.
The combination of AMH with either serum A or salA gave specificities that were quite high but the sensitiv-
ities were low. It has been suggested that A may reflect hyperandrogenism better than serum T8 and it has been 
suggested to be of diagnostic utility in European guidelines9; however, in combination with AMH, this study 
suggests that it may not be useful in making a diagnosis of PCOS with type A phenotype.
Limitations of this study were, in part, the converse of the strengths. This was a narrow group of individuals all 
with the type A PCOS phenotype, and therefore it is not known if an AMH >35 pmol/l with a raised FAI would be 
100% diagnostic for the B, C and D phenotypes. In addition, this was a narrow ethnic group and therefore more 
detailed studies of the different PCOS phenotypes with other ethnicities whose PCOS prevalence may differ, are 
required.
In conclusion, the combination of a raised AMH >35 pmol/l and a raised FAI is 100% specific for a diagnosis 
of PCOS with type A phenotype and conversely a AMH <35 pmol/l with a normal FAI was 100% specific for the 
exclusion of PCOS with type A phenotype, though sensitivity was poor; thus, the additional routine measurement 
of AMH may be of value that would help in cases of diagnostic uncertainty for PCOS with type A phenotype.
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